Investigating the clinical utility of a novel oral fluid heart failure point-of-care test.

研究一种新型口腔液心力衰竭即时检测的临床实用性。

• 批准号: 10045675
• 金额: $ 6.37万
• 依托单位: BIOHABIT LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10045675
• 关键词: Investigating; clinical; utility; novel; oral

Heart failure is common and carries a high mortality with around 40% of newly diagnosed patients dying each year in the UK. Although patients may complain of breathlessness, swollen legs and fatigue in the early stages, these symptoms are extremely non-specific, and 80% of cases are ultimately diagnosed in hospital.It is therefore critical that GPs and primary care teams are well equipped to make the diagnosis early and ensure timely medical intervention and specialist referral to a cardiologist. Whilst heart failure blood tests are already recommended by the National Institute for Health and Care Excellence for this purpose, up to one third of UK GPs still do not have access to the test. As a result, almost 200,000 patients each year in the UK are referred to secondary care based on signs and symptoms alone. Of these, two thirds will turn out not to have heart failure, costing the NHS more than £20 million of unnecessary annual expenditure.Meanwhile, although around a half of heart failure patients display symptoms that should trigger assessment in primary care, as many as 80% are diagnosed in the hospital emergency department in the context of a crisis. Once admitted, the additional associated financial burden amounts to more than £100 million due to long lengths of stay and poorer patient outcomes, much of which could be avoided.A new approach is clearly needed to save time and ensure efficient diagnosis for patients, but also to help GPs cut down consultation numbers and associated admin work and reduce the number of costly unnecessary referrals. A point-of-care test that could be performed in the surgery with an immediate result, that was inexpensive and non-invasive would allow GPs to rule in/out heart failure within the same consultation. Such a test would speed-up diagnosis massively, prevent unnecessary referrals and reduce hospitalisation rates with significant cost savings amounting to £110 per year.Biohabit Ltd is currently developing such non-invasive heart failure diagnostic test. The company has already demonstrated the proof-of-concept and is now starting clinical efficacy testing. Data and technical parameters generated in this project will allow the company to create a prototype of the proposed diagnostic device.Biohabit aims to sell the device to the NHS as well as health-conscious consumers, who will be able to purchase the test over-the-counter to assess the risk of developing heart failure and getting the upper hand in managing the cardiac health.

心力衰竭很常见，死亡率很高，在英国，每年约有 40% 的新诊断患者死亡。尽管患者在早期可能会抱怨呼吸困难、腿部肿胀和疲劳，但这些症状极不具有特异性，80。 % 的病例最终在医院得到诊断。因此，全科医生和初级保健团队必须具备充分的能力，以便及早做出诊断，并确保及时进行医疗干预并将专家转诊给心脏病专家，而国家已经建议进行心力衰竭血液检查。健康与护理研究所出于这一目的，多达三分之一的英国全科医生仍然无法进行检测，因此，英国每年有近 200,000 名患者仅根据体征和症状就被转诊至二级护理机构，其中三分之二是这样的。事实证明，他们并没有患上心力衰竭，这给 NHS 带来了超过 2000 万英镑的不必要的年度支出。与此同时，尽管大约一半的心力衰竭患者表现出应在初级保健中进行评估的症状，但多达 80% 的患者是在初级保健中被诊断出来的。医院紧急情况一旦入院，由于住院时间长和患者预后较差，额外的相关财务负担将超过 1 亿英镑，而其中大部分是可以避免的。显然需要一种新的方法来节省时间。并确保对患者进行有效的诊断，同时还可以帮助全科医生减少咨询次数和相关的管理工作，并减少昂贵的不必要的转诊次数。可以在手术中进行即时结果的即时检测。廉价且非侵入性将允许全科医生进行统治这样的测试将大大加快诊断速度，防止不必要的转诊并降低住院率，每年可节省 110 英镑的费用。Biohabit Ltd 目前正在开发这种非侵入性心力衰竭诊断。该公司已经展示了概念验证，目前正在开始临床功效测试，该项目中生成的数据和技术参数将使该公司能够创建所提议的诊断设备的原型。Biohabit 的目标是将该设备出售给NHS 以及注重健康的消费者，他们将能够在非处方药中购买该测试，以评估发生心力衰竭的风险并在管理心脏健康方面占据上风。